SciClone Pharmaceuticals Sings a Deal with FDA for Thymalfasin.....II-33

Abraxis BioScience, NCCN, and AstraZeneca Collaborates For Assessment of Abraxane,

&nbsp&nbspthe Anti-Cancer Drug.....II-33

1

$100

Oxford BioMedica Acquires Oxxon Therapeutics.....II-34

1

$100

7. FOCUS ON SELECT GLOBAL PLAYERS.....II-35

6

$395

Abraxis BioScience, Inc. (USA).....II-35

Astellas Pharma US, Inc. (USA).....II-35

Antigenics Inc. (USA).....II-35

1

$100

AVAX Technologies, Inc. (USA).....II-36

BioVex, Inc. (USA).....II-36

1

$100

GenVec, Inc. (USA).....II-37

GlaxoSmithKline Plc. (UK).....II-37

1

$100

Medarex Inc. (USA).....II-38

Merck KGAA (Germany).....II-38

Oxford Biomedica Plc. (UK).....II-38

1

$100

Pfizer, Inc. (USA).....II-39

Progen Pharmaceuticals Limited (Australia).....II-39

1

$100

Vical Inc. (USA).....II-40

1

$100

8. GLOBAL MARKET PERSPECTIVE.....II-41

Table 1: World Recent Past, Current & Future Analysis for Melanoma Therapeutics Market by Geographic Region - US, and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2007 through 2015 (includes corresponding Graph/Chart).....II-41

1

$350

Table 2: World Historic Review for Melanoma Therapeutics Market by Geographic Region - US, and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2001 through 2006 (includes corresponding Graph/Chart).....II-42

1

$350

Table 3: World 13-Year Perspective for Melanoma Therapeutics Market by Geographic Region - Percentage Breakdown of Sales for the US, and Rest of World Markets for the Years 2003, 2009 & 2015 (includes corresponding Graph/Chart).....II-43

1

$350

III. MARKET

24

$1950

1. THE UNITED STATES.....III-1

14

$595

A. Market Analysis.....III-1

Increasing Incidence of Melanoma Fuels Growth.....III-1

Table 4: Melanoma Incidence in the US by Gender: 2008 (includes corresponding Graph/Chart).....III-1

Table 9: Five-Year Survival Rate for Patients with Melanoma of Skin in the US (1996-2003): Percentage Share Breakdown by Race (includes corresponding Graph/Chart).....III-3

US Melanoma Fact Sheet: A Recapitulation.....III-3

1

$200

Major Players.....III-4

4

$150

Strategic Corporate Developments.....III-8

6

$175

B. Market Analytics.....III-14

Table 10: US Recent Past, Current & Future Analysis for Melanoma Therapeutics Market with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-14

Table 11: US Historic Review for Melanoma Therapeutics Market with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-14

Table 16: Mortality Due to Melanoma of Skin in the UK (2003-2005): Breakdown by Select Regions, and Gender (includes corresponding Graph/Chart).....III-17

1

$200

Major Players.....III-18

1

$75

Strategic Corporate Developments.....III-19

4

$150

B. Market Analytics.....III-23

Table 17: Rest of World Recent Past, Current & Future Analysis for Melanoma Therapeutics Market with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-23

1

$200

Table 18: Rest of World Historic Review for Melanoma Therapeutics Market with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-24